Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

GILD, MYL, WCRX – Hot Stocks at NASDAQ Healthcare Sector by

Gilead Sciences, Inc. (NASDAQ:GILD) decreased 0.43% to close at $39.64. GILD traded 8.78 million shares for the day and its earning per share remained $3.42. Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. The Company has operations in North America, Europe and Australia. The Company's products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. The Company has sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States.

Mylan Inc. (NASDAQ:MYL) increased 0.40% to close at $20.24. MYL traded 5.61 million shares for the day and its earning per share remained $0.72. Mylan Inc. (Mylan) is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients (APIs). It operates through two business segments: Generics and Specialty. The Generics Segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule or transdermal patch form, as well as API. The Specialty Segment engages mainly in the manufacture and sale of branded specialty nebulized and injectable products.

Warner Chilcott Plc (NASDAQ:WCRX) increased 0.30% to close at $23.69. WCRX traded 1.95 million shares for the day and its earning per share remained $2.04. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women's healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products.


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Disclosure: No positions